Determining health-related quality of life and health state utility values of urinary incontinence in women

Female Pelvic Medicine and Reconstructive Surgery

Volumn 17, Issue 6, 2011, Pages 305-307

  Patterson, Danielle ^a   Geisler, Benjamin P ^c   Morse, Abraham ^b  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NONE

Author keywords

Quality of life; Urinary incontinence; Utility value

Indexed keywords

SURVEYS;

GENERIC METHOD; GOLD STANDARDS; HEALTH-RELATED QUALITY OF LIVES; INTER QUARTILE RANGES; QUALITY OF LIFE; SANDVIK; SEVERITY INDEX; STANDARD GAMBLE; STATISTICALLY SIGNIFICANT DIFFERENCE; STRESS URINARY INCONTINENCES; URINARY INCONTINENCE; UTILITY VALUE; VISUAL ANALOG SCALE;

HEALTH;

EID: 84856482909     PISSN: 21518378     EISSN: None     Source Type: Journal    
DOI: 10.1097/SPV.0b013e31823c040     Document Type: Article

References (13)

1. Manca A, Sculpher MJ, Ward K, et al. A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG 2003;110:255-262. (Pubitemid 36298907)
2. Wu JM, Visco AG, Weidner AC, et al. Is burch colposuspension ever cost-effective compared with tension-free vaginal tape for stress incontinence? AJOG 2007;197:62e1-5.
3. Subak LL, Brown JS, Kraus SR, et al. The "costs" of urinary incontinence for women. Obstet Gynecol 2006;107:908-916.
4. Subak LL, Brubaker L, Chai TC, et al. High costs of urinary incontinence among women electing surgery to treat stress incontinence. Obstet Gynecol 2008;111:899-907. (Pubitemid 351482622)
5. Culligan PJ, Myers JA, Goldberg RP, et al. Elective cesarean section to prevent anal incontinence and brachial plexus injuries associated with macrosomia - a decision analysis. Int Urogyncol J 2005;16:19-28. (Pubitemid 40109750)
6. Mittman N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15:369-376. (Pubitemid 29190028)
7. Schultz SE, Kopec JA. Impact of chronic conditions. Health Reports 2003;14:41-53.
8. Bracco A, Jönsson B, Ricci JF, et al. Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study. Value Health 2007; 10(4):238-246. (Pubitemid 47077249)
9. Botlero R, Davis SR, Urquhart DM, et al. Incidence and resolution rates of different types of urinary incontinence in women: findings from a cohort study. J Urol 2011;185(4):1331-1337.
10. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001;98(3):398-406.
11. Sandvik H, Seim A, Vanvik A, et al. A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests. Neurourol Urodyn 2000;19: 137-145. (Pubitemid 30124033)
12. Johnson JA, Coons SJ, Ergo A, et al. Valuation of EuroQOL (ED-5Q) Health States in an adult US sample. Pharmacoeconomics 1998;13:421-423.
13. US EQ-5D Scoring Algorithm for SAS. Available at: http://www.ahrq.gov/ rice/EQ5Dscore.htm. Accessed on March 28, 2011.